秦兰,刘晓,李巍,吴雪琴,白玉盛

• 1:新疆医科大学附属医院中医医院血液科

摘要(Abstract)：

目的探讨泼尼松加用益气补肾活血中药治疗慢性免疫性血小板减少症(CITP)的临床疗效和安全性。方法选择2011年1月-2013年12月新疆医科大学附属中医医院血液科收治的慢性免疫性血小板减少症患者120例,按自愿原则随机分为对照组(泼尼松)和观察组(泼尼松+益气补肾活血中药),每组60例。对照组采用泼尼松1mg·kg-1·d-1治疗;治疗组采用泼尼松治疗基础上,加益气补肾活血中药治疗。疗程结束后比较两组患者疗效、CD19+/CD20+淋巴细胞数及不良反应。结果对照组和观察组患者的总有效率分别为75.0%和95.0%,差异有统计学意义(P<0.05)。两组患者治疗后的CD19+/CD20+淋巴细胞数均下降,差异有统计学意义(P<0.05),观察组患者较对照组患者下降更为明显,差异有统计学意义(P<0.05)。观察组患者血糖升高、血压升高、库欣样症状及神经精神症状等不良反应较对照组患者明显减少,差异有统计学意义(P<0.05)。结论采用泼尼松加用益气补肾活血中药是临床上治疗慢性免疫性血小板减少症患者更为安全有效的方案之一,值得临床积极推广应用。

关键词(KeyWords)： 泼尼松;益气补肾活血中药;慢性免疫性血小板减少症;临床疗效

Abstract:

Keywords:

基金项目(Foundation): 新疆维吾尔自治区自然科学基金面上项目(201233146-18)

作者(Author): 秦兰,刘晓,李巍,吴雪琴,白玉盛

参考文献(References)：

• [1]Cooper N,Bussel J.The pathogenesis of immune thrombocytopaenic purpura[J].Br J Hematol,2006,133(4):364-374.
• [2]Rodeghiero F,Slasi R,Germheimer T,et al.Standardization of terminology,definitions and outcome criteria in immune thrombocytopenic purpura of adults and children;report from an internation working group[J].Blood,2009,113(11):2386-2398.
• [3]Stasil R,Evangelistal ML,Stipa E,et al.Idiopathic thrombocytopenic purpura:current concepts in pathophysiology and management[J].Thtomb Haemost,2008,99(1):4-13.
• [4]中华医学会血液学分会血栓与止血学组.成人原发免疫性血小板减少症诊治的中国专家共识(修订版)[J].中华血液学杂志2011,32(3):214-416.
• [5]Amold DM,Dentali F,Crowther MA,et al.Systematic review:efficacy and safety of rituximab for adults with idiopathie thrombocytopenic purpura[J].Medicine,2007,146(1):25-33.
• [6]Zhang L,Qian Y,Cheng S,et al.The clinical efficacy of rituximab therapy for the treatment of refractory immune thrombocytopenic purpura[J].Clin Med J China,2008,15(4):522-523.
• [7]Zhou B,Zhao H,Yang RC,et al.Multi-dysfunctional pathohuysiology in ITP[J].Crit Rev Oncol Hematol,2005,54(2):107-116.
• [8]谭志新.中西医结合治疗特发性血小板减少性紫癜48例临床观察[J].长春中医药大学学报,2011,27(5):795-796.
• [9]马柔.应对慢性免疫性血小板减少症患者自身免疫及免疫缺陷同时存在矛盾的策略[J].中国中西医结合杂志,2011,31(8):1029-1032.
• [10]Quan RC.Research on the clinical efficacy and mechanism of Yiqi Tongyang Decoction in c ITP and r ITP patients[D].Beijing:China Academy of Traditional Chinese Medicine,2010.
• [11]朱会兰.益气通阳汤治疗慢性免疫性血小板减少症临床疗效及免疫功能探讨[D].北京:北京中医药大学,2013.
• [12]Emmerich F,Bal G,Barakat A,et al.High-level serum B-cell activating factor and platelet-specific antigens and platelet glycoproteins[J].Dan Med Bull,1992,39(4):343-354.
• [13]Pescvite MD.Rituximab,an anti-CD20 monoclonal antibody:history and mechanism of action[J].Am J Transplant,2006,6(1):859-866.
• [14]Stasi R,Cooper N,Del Poeta G,et al.Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with nituximab[J].Blood,2008,93(6):930-939.